Royalty Pharma EV/EBIT RPRX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Oct 23, 2026: 30.2×
5-year median: 24.0×
Against its 5-year history: 85th; percentile: 0 is its lowest day, 100 its highest
5-year range: 14.4× to 38.9×
Peer median: 28.3×

Royalty Pharma's EV/EBIT is 30.2× as of Oct 23, 2026.

That is above its 5-year median of 24.0×, higher than on 85% of days in the last 5 years.

Over that time it ranged from 14.4× in May 2025 to 38.9× in Nov 2022.

The median for 10 healthcare stocks of a similar size is 28.3×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	30.2×	21.7×	30.3×
2025	21.9×	14.4×	22.3×
2024	15.9×	15.7×	27.5×
2023	25.1×	23.0×	35.9×
2022	36.0×	20.3×	38.9×
2021	20.5×	16.5×	24.5×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

Company	EV/EBIT
RPRXRoyalty Pharma	30.2×
RMDResMed	18.7×
BIIBBiogen	26.3×
CNCCentene	21.8×
ZTSZoetis	11.6×
MTDMettler-Toledo International	30.5×
ILMNIllumina	47.7×
GEHCGE HealthCare Technologies	14.7×
ONCBeOne Medicines	42.2×
IDXXIDEXX Laboratories	30.3×
WATWaters	129×
Peer median	28.3×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.